This message contains My NCBI what's new results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM).
Do not reply directly to this message.
Sender's message:
Sent on Friday, 2010 Apr 09Search kinetoplastids OR kinetoplastid OR Kinetoplastida OR "trypanosoma brucei" OR leishmania OR brucei OR leishmaniasis OR "African trypanosomiasis"
Click here to view complete results in PubMed. (Results may change over time.)
To unsubscribe from these e-mail updates click here.
| PubMed Results |
| 1. | J Biophotonics. 2010 Apr 7. [Epub ahead of print]Monitoring the efficacy of antimicrobial photodynamic therapy in a murine model of cutaneous leishmaniasis using L. major expressing GFP.Latorre-Esteves E, Akilov OE, Rai P, Beverley SM, Hasan T.Wellman Centre for Photomedicine, Massachusetts General Hospital, Department of Dermatology, Harvard Medical School, Boston, MA 02114, USA. AbstractA murine model of cutaneous leishmaniasis with green fluorescent protein positive (GFP+) L. major enables the monitoring of parasitic load via measurements of GFP fluorescence intensity, allowing for a faster and more efficient way of monitoring the clinical outcome of photodynamic therapy (PDT). This model may provide new insights on the phototoxic aspects in PDT. Although PDT regimens may be somewhat different in humans, it is expected that the developed model will facilitate the optimization and clinical translation of PDT as a therapy for cutaneous leishmaniasis and the eventual development of topical PDT treatments for other granulomatous infections. ((c) 2010 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim). |
| PMID: 20376860 [PubMed - as supplied by publisher] | |
| 2. | J Clin Rheumatol. 2010 Apr;16(3):125-8.Mucocutaneous leishmaniasis masquerading as wegener granulomatosis.Brahn E, Pegues DA, Yao Q, Craft N.From the Divisions of *Rheumatology, UCLA School of Medicine, daggerInfectious Diseases, UCLA School of Medicine, and double daggerDermatology and Infectious Diseases, Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance, CA. AbstractA 43-year-old Brazilian female presented in 2001 with nasal stuffiness and sinusitis. A biopsy was consistent with limited Wegener's granulomatosis although antineutrophil cytoplasmic antibodies were negative. Her nasal inflammation progressed despite trials of prednisone, methotrexate, and azathioprine. A septal perforation developed and a repeat biopsy showed granulomatous inflammation. In 2006 the patient was referred to Division of Rheumatology, University of California, Los Angeles. The nose was grossly erythematous and a magnetic resonance imaging revealed nasal destruction and sinusitis. Palatine biopsies showed chronic inflammation. Cyclophosphamide at 150 mg/d resulted in markedly improved mucocutaneous lesions. The patient developed a leg and arm rash in 2007. A skin biopsy was positive for Leishmania braziliensis. The cyclophosphamide was discontinued and amphotericin B was initiated with transient benefit. Remission was achieved with pentavalent antimony.Despite multiple nasopharyngeal biopsies, for a 6-year span, mucocutaneous leishmaniasis masqueraded as Wegener's granulomatosis. Cyclophosphamide not only resulted in clinical improvement, due to reduced inflammatory response, but also allowed widespread cutaneous dissemination. |
| PMID: 20375822 [PubMed - in process] | |
| 3. | J Innate Immun. 2010;2(2):195-200. Epub 2009 Oct 22.Expression of the Inhibitory CD200 Receptor Is Associated with Alternative Macrophage Activation.Koning N, van Eijk M, Pouwels W, Brouwer MS, Voehringer D, Huitinga I, Hoek RM, Raes G, Hamann J.Department of Neuroimmunology, Netherlands Institute for Neuroscience, Institute of the Royal Netherlands Academy for Arts and Sciences, Amsterdam, The Netherlands. AbstractClassical macrophage activation is inhibited by the CD200 receptor (CD200R). Here, we show that CD200R expression was specifically induced on human in vitro polarized macrophages of the alternatively activated M2a subtype, generated by incubation with IL-4 or IL-13. In mice, peritoneal M2 macrophages, elicited during infection with the parasites Taenia crassiceps or Trypanosoma brucei brucei, expressed increased CD200R levels compared to those derived from uninfected mice. However, in vitrostimulation of mouse peritoneal macrophages and T. crassiceps infection in IL-4-/- and IL-4R-/- mice showed that, in contrast to humans, induction of CD200R in mice was not IL-4 or IL-13 dependent. Our data identify CD200R as a suitable marker for alternatively activated macrophages in humans and corroborate observations of distinct species- and/or site-specific mechanisms regulating macrophage polarization in mouse and man. Copyright © 2009 S. Karger AG, Basel. |
| PMID: 20375636 [PubMed - as supplied by publisher] | |
| 4. | Clin Microbiol Rev. 2010 Apr;23(2):324-49.Cardiac involvement with parasitic infections.Hidron A, Vogenthaler N, Santos-Preciado JI, Rodriguez-Morales AJ, Franco-Paredes C, Rassi A Jr.Department of Medicine, Emory University School of Medicine, 550 Peachtree St. MOT, 7th Floor, TravelWell Clinic, Atlanta, GA 30308, USA. AbstractParasitic infections previously seen only in developing tropical settings can be currently diagnosed worldwide due to travel and population migration. Some parasites may directly or indirectly affect various anatomical structures of the heart, with infections manifested as myocarditis, pericarditis, pancarditis, or pulmonary hypertension. Thus, it has become quite relevant for clinicians in developed settings to consider parasitic infections in the differential diagnosis of myocardial and pericardial disease anywhere around the globe. Chagas' disease is by far the most important parasitic infection of the heart and one that it is currently considered a global parasitic infection due to the growing migration of populations from areas where these infections are highly endemic to settings where they are not endemic. Current advances in the treatment of African trypanosomiasis offer hope to prevent not only the neurological complications but also the frequently identified cardiac manifestations of this life-threatening parasitic infection. The lack of effective vaccines, optimal chemoprophylaxis, or evidence-based pharmacological therapies to control many of the parasitic diseases of the heart, in particular Chagas' disease, makes this disease one of the most important public health challenges of our time. |
| PMID: 20375355 [PubMed - in process] | |
Publication Types:
|
| 5. | J Enzyme Inhib Med Chem. 2010 Feb;25(1):111-5.Trypanocidal activity of the ethyl esters of N-propyl and N-isopropyl oxamates on intracellular amastigotes of Trypanosoma cruzi acute infected mice.Aguirre-Alvarado C, Zaragoza-Martínez F, Rodríguez-Páez L, Téllez-Rendón JL, Nogueda B, Baeza I, Wong C.Departamento de Bioquímica, Escuela Nacional de Ciencias Biológicas-Instituto Politécnico Nacional, Mexico City, Mexico. AbstractIn this investigation we studied the trypanocidal activity of the ethyl esters of N-propyl (Et-NPOX) and N-isopropyl (Et-NIPOX) oxamates on bloodstream trypomastigotes and on the clinically relevant intracellular amastigotes of Trypanosoma cruzi acute infected mice. In the infected and treated mice, the levels of parasitemia were drastically reduced between days 15 and 20 of treatment and almost to zero between days 35 and 40. We also found that Et-NPOX completely eliminated amastigote nests in the myocardium of mice infected with INC-5 or NINOA T. cruzi strain, and in skeletal muscle the reduction in the number of amastigote nests was between 60 and 80% in both strains. Also, Et-NIPOX reduced by 60-80% the number of amastigote nests in the myocardium and skeletal muscle of mice infected with these T. cruzi strains. In contrast, nifurtimox, used for comparison, produced a reduction of amastigote nests of only 20-40% in the studied tissues in both strains. |
| PMID: 20030515 [PubMed - indexed for MEDLINE] | |
| Related articles | |
 | |
Publication Types:
MeSH Terms:
Substances:
|
| 6. | J Enzyme Inhib Med Chem. 2010 Feb;25(1):62-7.Cruzain inhibition by hydroxymethylnitrofurazone and nitrofurazone: investigation of a new target in Trypanosoma cruzi.Trossini GH, Malvezzi A, T-do Amaral A, Rangel-Yagui CO, Izidoro MA, Cezari MH, Juliano L, Chin CM, Menezes CM, Ferreira EI.Departamento de Farmácia, Faculdade de Ciências Farmacêuticas, USP, São Paulo, Brazil. trossini@usp.br AbstractNitrofurazone (NF) and its derivative, hydroxymethylnitrofurazone (NFOH), have presented antichagasic activity. NFOH has higher activity and lower mutagenicity. The aim of this work was to assess whether NF and its derivative NFOH would also be inhibitors of cruzain, besides their trypanothione reductase inhibitory activity. In vitro cruzain inhibition tests were performed for both compounds, and the 50% inhibitory concentration (IC50) for NF and NFOH presented values of 22.83 +/- 1.2 microM and 10.55 +/- 0.81 microM, respectively. AM1 semi-empirical molecular modeling studies were performed to understand the activity of the compounds, corroborating the observed cruzain inhibitory activity. |
| PMID: 20030510 [PubMed - indexed for MEDLINE] | |
| Related articles | |
| | |
Publication Types:
MeSH Terms:
Substances:
|
| 7. | J Enzyme Inhib Med Chem. 2010 Feb;25(1):29-37.Synthesis and leishmanicidal activity of 2,3,4-substituted-5-imidazolones.Khan KM, Mughal UR, Ambreen N, Samreen, Perveen S, Choudhary MI.H. E. J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan. hassaan2@super.net.pk AbstractTwenty-nine imidazolones 1-29 were synthesized and were randomly screened for their in vitro anti-leishmanial potential. Compound 17 showed a good anti-leishmanial activity with an IC50 value of 12.98 +/- 0.32 microg/mL. Compounds 14 and 24 were also found to be moderately active (IC50 values 28.20 +/- 0.03 and 41.12 +/- 0.32 microg/mL, respectively). The activity was compared with that of standard drugs, amphotericin B (IC50 = 0.12 +/- 0.41 microg/mL) and pentamidine (IC50 = 2.56 +/- 0.10 microg/mL). |
| PMID: 20030507 [PubMed - indexed for MEDLINE] | |
| Related articles | |
| | |
Publication Types:
MeSH Terms:
Substances:
|
No comments:
Post a Comment